My Top 5 Stocks to Buy for 2025 Part – 02
It’s that time of the year again. I’m not referring to buying gifts and preparing holidays meals— all though that may be part of your agenda too. It’s time to look back on your portfolio’s performance and plan for the year ahead.
it’s been a solid year for many with all three indexes heading for triple-digit gains, and with the right mix of stocks we might make 2025 a winning one too. Most importantly though, remember to focus on the long term, as gains over a number of years are what we are really looking for–so don’t worry if your portfolio hasn’t perform as well as you’d hoped during any particular year, including this one.
Need some more inspiration for stocks to buy right now? Here are my top 10 buys — in on particular order — for 2025 and beyond. Most of these stocks have a solid earning track record (expect for the clinical-stage Biotech that hasn’t yet generated products revenue). And they all have bright long term prospect.
1. Vertex Pharmaceuticals
Vertex Pharmaceuticals (NASDAQ:VRTX) is a profile leader in this cystic Fibrosis (CF) treatment market with CF drugs bringing in a blockbuster revenue year after year.
The company has shown investor that it has what it takes to expand into other areas too. It won approval for a blood disorders treatment a year ago. And No it’s awaiting a regulatory decision on a potential drug that could be big for the company. I’m talking about suzetrigine for moderate – to – severe acute pain.
vertex is the potential product as a multibillion -dollar opportunity considering the limited options for pain treatment today. The company expects a regulatory decision next month — that and a potential launch with revenue growth to follow could make Vertex a winner next year.
2. Crowdstrike
CrowdStrike (NASDAQ:CRWD) is a top cyber security company that met a major headwind this year. A faulty software update from crowdstrike lead to the biggest information technology outage ever.
this is weighing on earning as the company offers customer compensation packages — but this packages also are encouraging them to expend their contracts with the security giant. So, over time, this gift of customer could bring in more revenue for crowd strike too.
Importantly, crowdstrike client stuck with it after the outage and annual recurring revenue continues to advance in the double digits. The company expects the impact of the outage to lessen by late next year, opening up the door to more growth down the road.
3. Abbott Laboratories
Abbott laboratories (NYSE:ABT) May not have one precise catalyst coming up, but it’s diverse business and dividend payments make it an excellent addition to any portfolio.
I like Abbott structure with businesses In medical devices, diagnostics, nutrition and established pharmaceuticals. This range of operations means that if one area meets headwinds, other can compensate. This has been the case recently diagnostics revenue slipped as COVID testing sales fall, but medical devices sells advance in the double digits.
Abbott has increased its quarterly dividend payout by 60% since 2020 — and the company track record of boosting is dividend for more than 50 years suggests rewarding shareholders remain a priority.
4. American Express
American Express (NYSE:AXP) Is another top performing stock this year advancing 60%. The credit card jaint makes money through membership fees, interest on customer balances and transactions at merchants accepting the card. Its position in the premium market has proven to be a winning strategy over time, and growth of the younger audience says that could continue.
In the recent quarter American Express set millennial and Gen-Z customer make up 80% of new US consumer gold card accounts — and this is the fastest growing consumer group for American Express in the US. In the quarter The company reported record revenue of 16.6 billion and card fee revenue and members spending both gained.
So, this well established company could offer plenty of growth ahead, powered by a new generation of consumer.
5. Palantir Technologies
Some say palantir Technologies (NASDAQ:PLTR) looks expensive today, trading for nearly 200x forward earning estimates. After soring more than 300% this year. But its important to considered the companies growth. The AI driven software players has seen sales to Commercial customer takeoff — even as it traditional government customer revenue continuous to climb.
In the recent quarter US commercial revenue Rose 54% and US government revenue increased 40%. On top of this, Palantir reported its highest quarterly Profit ever. Considering it launched its Artificial Intelligence platform just a year ago and commercial customer growth seems to be in its early days, this stock could have much further to go overtime.
That’s why it makes a solid by for growth investor for 2025.